GSK severe asthma drug progresses to Phase III – InPharm


InPharm

GSK severe asthma drug progresses to Phase III
InPharm
The Phase IIb DREAM study was testing mepolizumab in patients with severe eosinophilic asthma, a condition where organs are damaged by the over-production of white blood cells. The year-long study, which involved 621 patients, found the number of
GSK asthma drug cuts symptoms 52%; ready for PhIIIPharma Times
GSK drug halves attacks in hard-to-treat asthmaBusiness Recorder (blog)
Drug 'could cut asthma A&E visits'World First Travel Insurance
The Inquisitr –Zenopa
all 6 news articles »

View full post on asthma – Google News

NICE consults on asthma drug reducing procedure – InPharm

NICE consults on asthma drug reducing procedure
InPharm
NICE has launched a consultation in the UK on a new medical procedure which, if it proves safe and effective, may be a threat to established asthma drugs. Bronchial thermoplasty is the first non-drug asthma treatment the health watchdog has looked at,
NICE issue draft guidance on surgery for severe asthmaHealthcare Today
NICE to consider first non-drug treatment for asthmaOnMedica

all 3 news articles »

View full post on asthma – Google News